AFT Pharmaceuticals develops Maxigesic Rapid

Company News

by Rachael Jones

AFT Pharmaceuticals (ASX:AFP) has successfully completed development of a faster release version of its dual action pain-killer, Maxigesic.

Maxigesic comprises two active ingredients, paracetamol and ibuprofen.

A new formulation of Maxigesic has been developed which releases one of the key components, ibuprofen, much faster in comparison with a standard Maxigesic tablet.

Additional Intellectual Property has been generated around these findings and a further patent application has also been recently filed.

The market defined by Euromonitor in 2018 for oral dose forms of analgesics for adults is close to US$4 billion.

Shares in AFT Pharmaceuticals (ASX:AFP) last traded at $1.98.

 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.